| Name | Title | Contact Details |
|---|
The Company was founded in April 1997 by Robert Rosenbluth and Brian Cox and incorporated as MicroVention, Inc. in September.
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
N L Communications is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Union Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Union Hospital is based in Dover, OH. You can find more information on Union Hospital at www.unionhospital.org